Novel heteroaryl derivatives, their preparation and use
CA 2395984 A1 · Owner: Mikkelsen, Gitte · Inventors: Andersen, Kim; Rottlander, Mario; Moltzen, Ejner Knud
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A heteroaryl derivative having the formula (I) any of its enantiomers or any mixture thereof, or an acid addition salt thereof wherein X is -O-, -S-, or -, CR4R5-; and Y is -CR6R7- -CR6R7-CR8R9-, or -CR6=CR7-; or X and Y together form a group -CR4=CR5-, or -CR4=CR5-CR6R7-; Z is -Oor -S-; W is N, C, or , CH; n is 2, 3, 4 5, 6, 7, 8, 9 or 10; m is 2 or 3: A is O or S wherein the dotted lines mean an optional bond. The compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder depression, social phobia and eating disorders and neurological disorders such as , psychosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 29, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 29, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 29, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.